Applied Tissue Technologies
Applied Tissue Technologies LLC, founded in 2000 and headquartered in Hingham, MA, is dedicated to advancing wound healing technologies driven by science. The company focuses on medical innovation, developing proprietary devices and patented treatment methods to improve wound care efficiency globally, including in developing countries. Their research emphasizes Prolonged Field Care and Regenerative Medicine, supported by the US Department of Defense, US Army, Defense Health Agency, and SBIR. They aim to revolutionize negative pressure wound therapy with innovative, foamless, and simplified devices that enable effective treatment and topical delivery of therapeutics.
Industries
Nr. of Employees
small (1-50)
Applied Tissue Technologies
99 Derby Street, Suite 200, Hingham, MA 02043
Patents
Products
Embossed single-component negative pressure wound dressing
A single-layer, flexible, transparent dressing with embossed microstructures and integrated adhesive rim that distributes negative pressure evenly without separate foam or gauze filler and supports topical delivery of therapeutics.
Sterile micro-autografting kit for minced split-thickness skin grafting
A sterile, hand-powered, single-use kit for harvesting, mechanically preparing, and applying minced split-thickness skin autografts to expand donor site coverage and enable outpatient grafting procedures.
Embossed single-component negative pressure wound dressing
A single-layer, flexible, transparent dressing with embossed microstructures and integrated adhesive rim that distributes negative pressure evenly without separate foam or gauze filler and supports topical delivery of therapeutics.
Sterile micro-autografting kit for minced split-thickness skin grafting
A sterile, hand-powered, single-use kit for harvesting, mechanically preparing, and applying minced split-thickness skin autografts to expand donor site coverage and enable outpatient grafting procedures.
Services
Sponsorship and operational support for Phase II studies, randomized controlled trials and case series evaluating wound therapy devices and procedures.
Design and coordination of GLP preclinical safety and efficacy studies including comparative swine-model testing and topical delivery penetration studies.
Coordination with exclusive contract manufacturers for sterile single-use device production.
Experience obtaining medical device regulatory clearances and maintaining quality management system certifications (e.g., ISO 13485).
Sponsorship and operational support for Phase II studies, randomized controlled trials and case series evaluating wound therapy devices and procedures.
Design and coordination of GLP preclinical safety and efficacy studies including comparative swine-model testing and topical delivery penetration studies.
Coordination with exclusive contract manufacturers for sterile single-use device production.
Experience obtaining medical device regulatory clearances and maintaining quality management system certifications (e.g., ISO 13485).
Expertise Areas
- Negative pressure wound therapy (NPWT) platform development
- Topical drug delivery for wound care
- Micro-autografting and split-thickness skin graft expansion
- Preclinical GLP testing and animal models (swine)
Key Technologies
- Negative pressure wound therapy (NPWT)
- Embossed microstructured single-layer dressings
- Sealed wound microenvironment drug delivery
- Micro-autografting (minced split-thickness skin graft technique)
News & Updates
Applied Tissue Technologies LLC (ATT) has won U.S. FDA clearance for a negative pressure wound therapy (NPWT) system that eliminates foam as a potential impediment to complete wound healing.
ATT announced FDA 510(k) clearance of its Negative Pressure Wound Therapy product, the Platform Wound Dressing (PWD®), a first-of-its-kind embossed NPWT device without foam or gauze.
The USPTO issued a patent for a device employing negative pressure, simplifying NPWT treatment by eliminating traditional dispersing methods, with a design that comes into direct contact with the wound and stimulates granulation tissue.
The company received a patent in China for a device that simplifies NPWT by eliminating foam or gauze, using a microstructure design for micro-environment creation.
A study describing the use of the XPANSION Skin Grafting Instrument Kit, showing significant wound healing results in a large burn case in Iraq.
XPANSION and micrografting techniques were used on a burn victim in Iraq, enabling a large coverage and normal life recovery.
Applied Tissue Technologies LLC (ATT) has won U.S. FDA clearance for a negative pressure wound therapy (NPWT) system that eliminates foam as a potential impediment to complete wound healing.
ATT announced FDA 510(k) clearance of its Negative Pressure Wound Therapy product, the Platform Wound Dressing (PWD®), a first-of-its-kind embossed NPWT device without foam or gauze.
The USPTO issued a patent for a device employing negative pressure, simplifying NPWT treatment by eliminating traditional dispersing methods, with a design that comes into direct contact with the wound and stimulates granulation tissue.
The company received a patent in China for a device that simplifies NPWT by eliminating foam or gauze, using a microstructure design for micro-environment creation.
A study describing the use of the XPANSION Skin Grafting Instrument Kit, showing significant wound healing results in a large burn case in Iraq.
XPANSION and micrografting techniques were used on a burn victim in Iraq, enabling a large coverage and normal life recovery.